We provided evidence that PIK3CA E545K mutation was correlated with lower histological differentiation, later clinical stage, and poorer prognosis; thus, PIK3CA E545K mutation is a potential molecular biomarker for predicting prognosis in CRC patients. This evidence concerns the gene PIK3CA and colorectal carcinoma.